The largest 3D-map of (mouse) brain has arrived 🧠

AI x Bio space is on fire ...

www.techlifesci.com/p/weekly-tec...

Boston/HK-based AI biotech Insilico Medicine released industry benchmarks—demonstrating an average 13-month timeline to preclinical drug candidate nomination, a reduction from the traditional 2.5- to 4-year process.

JUST IN: A startup Latent Labs, led by former DeepMind's lead scientist Dr. Simon Kohl, raised $50M to build AI foundation models for protein design 💰 🚀

Image credit: Latent Labs

Sometimes you just need to unplug and look above

I think its pretty much a trend now when top tech executives launch AI drug discovery startups.

Everyone wants to solve biology by computation...

It seems possible for newcomers

I don't mean anything else but humour

(credit: OstanniyCapitalist)

That's my definition of AI drug discovery platform. Thoughts?

Crazy, but rumors have it there might be a second $1B round for "AIxBio" startup in less than a year...

According to report by Kyle LaHucik, Sam Altman's Retro Biosciences eyes $1B to extend lifespan via aiming its foundation model at cellular reprogramming.

The other one was Xaira Tx...

Yes, we have a Substack newsletter, if anything...

Cool news from gen AI camp in drug discovery:

Boston based Insilico Medicine doses first patient with AI-designed pan-TEAD inhibitor.

And by the way, they also just published first practical workflow of quantum computing in drug design! (comment for more details pls)

Probably, one of the largest collaborative efforts in biotech, since the Human Genome Project: the Human Cell Atlas has arrived! 🧬

This isn’t just another dataset—this is the blueprint of human biology, built cell by cell, tissue by tissue, organ by organ.

If you suddenly decided to start on a new media platform in 2025... just know this

Chip makers fight for new markets, and healthcare is lucrative as never before

No, its not California

All 'true' AI drug discovery companies are actually software companies.

We fantisize about AI as some kind of brain living in a jar... but the reality is, it is a software product, and should be treated as one.

Anyone who claims they are AI-driven should be able to show GUI or feature spec. No?

If AI system can screen and suggest the most optimal and safe drug-like molecule, it could also suggest the most toxic one.

I have a curious study about it, let me know if this topic of interest...

My entire view of AI in bio is this: we already have sufficiently capable algo-s to improve drug discovery. But we do not have enough domain specific data to reach that. So, the race now is not for novel super AI, but for data acquisition capabilities. It is costly. Hence, huge $ valuations.

Where are we now with AI-driven drug discovery?

There is a new article in Clinical Pharmacology & Therapeutics raising some important questions for 2025... read it!

ascpt.onlinelibrary.wiley.com/journal/1532...